Orotic acid (OA) is an intermediate of
pyrimidine nucleotide biosynthesis. Hereditary deficiencies in some
enzymes associated with
pyrimidine synthesis or the
urea cycle induce OA accumulation, resulting in orotic aciduria. A link between patients with orotic aciduria and
hypertension has been reported; however, the molecular mechanisms remain elusive. In this study, to elucidate the role of OA in vascular
insulin resistance, we investigated whether OA induced endothelial dysfunction and
hypertension. OA inhibited
insulin- or
metformin-stimulated
nitric oxide (NO) production and endothelial
NO synthase (eNOS) phosphorylation in human umbilical vein endothelial cells. A decreased
insulin response by OA was mediated by impairment of the
insulin-stimulated
phosphoinositide 3-kinase (PI3K)-protein
kinase B (PKB/Akt) signaling pathway in cells overexpressing the p110-PI3K catalytic subunit. Impaired effects of
metformin on eNOS phosphorylation and NO production were reversed in cells transfected with constitutively active
AMP-activated protein kinase. Moreover, experimental induction of orotic aciduria in rats caused
insulin resistance, measured as a 125% increase in the homeostasis model assessment, and
hypertension, measured as a 25% increase in systolic blood pressure. OA increased the plasma concentration of
endothelin-1 by 201% and significantly inhibited
insulin- or
metformin-induced vasodilation. A compromised
insulin or
metformin response on the Akt/eNOS and
AMP-activated protein kinase/eNOS pathway was observed in aortic rings of OA-fed rats. Taken together, we showed that OA induces endothelial dysfunction by contributing to vascular and systemic
insulin resistance that affects
insulin- or
metformin-induced NO production, leading to the development of
hypertension.